Astrazeneca Pharma India Ltd.
NSE: ASTRAZEN | BSE: 506820
₹8,141.00
₹-63.00
(-0.77%)
As on 08-Jul-2026IST
Market cap
₹20,375 Cr
Revenue (TTM)
₹2,276 Cr
P/E Ratio
108.7
P/B Ratio
23.3
Div. Yield
0.4 %
Quality Score
8/10
Growth Score
6/10
Valuation Score
3/10
Momentum Score
4/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹188 Cr
-
ROE
15.7 %
-
ROCE
21.3 %
-
Industry P/E
35.92
-
EV/EBITDA
68.6
-
Debt to Equity
0
-
Book Value
₹349.1
-
EPS
₹76.6
-
Face value
2
-
Shares outstanding
25,000,000
10 Years Aggregate
CFO
₹603.38 Cr
EBITDA
₹1,116.84 Cr
Net Profit
₹709.32 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
| -9.8 | -5.3 | 4.5 | -11.0 | 29.5 | 17.7 | 22.7 |
|
BSE Healthcare
| 13.3 | 4.9 | 18.1 | 9.6 | 23.8 | 13.6 | 11.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
| 25.5 | 29.4 | 67.6 | 6.4 | -33.1 | 76.4 | 81.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
8,141.0 | 20,375.4 | 2,275.6 | 187.5 | 10.3 | 22.9 | 108.7 | 23.3 |
| 2,528.4 | 19,209.7 | 2,187.2 | 649.7 | 31.5 | 19 | 30 | 5.4 | |
| 1,979.4 | 12,079.7 | 1,403.2 | 185.1 | -- | 27.4 | 65.3 | 16.2 | |
| 1,416.0 | 19,593.6 | 3,129.4 | 647.4 | 26.9 | 18.1 | 31.6 | 5.0 | |
| 2,435.8 | 39,081.6 | 4,147.8 | 709.5 | 22.3 | 19.1 | 55.1 | 9.4 | |
| 4,532.1 | 20,708.6 | 2,519.7 | 722.4 | 33.6 | 17.2 | 28.7 | 4.9 | |
| 6,262.5 | 10,405.6 | 1,408.0 | 326.9 | 30.8 | 57.1 | 31.8 | 19.8 | |
| 3,381.6 | 7,782.6 | 1,773.8 | 309.8 | 24.0 | 43.1 | 25.1 | 10.0 | |
| 595.4 | 11,632.2 | 1,538.1 | 226.2 | 20.4 | 9 | 47.8 | 4.5 | |
| 1,080.8 | 9,951.0 | 4,858.7 | 574.1 | 14.9 | 19.7 | 17.9 | 3.2 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Astrazeneca Pharma
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions;... oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. Read more
-
Incorporated
1979
-
Chairman
Shilpa Divekar Nirula
-
Managing Director
--
-
Group
Astrazeneca Pharma India - MNC
-
Headquarters
Bengaluru, Karnataka
-
Website
Looking for more details about Astrazeneca Pharma India Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Astrazeneca Pharma
What is the current share price of Astrazeneca Pharma India Ltd Today?
The share price of Astrazeneca Pharma India Ltd is ₹8,141.00 (NSE) and ₹8,150.15 (BSE) as of 08-Jul-2026 IST. Astrazeneca Pharma India Ltd has given a return of 29.51% in the last 3 years.
What is the current PB & PE ratio of Astrazeneca Pharma India Ltd?
The P/E ratio of Astrazeneca Pharma India Ltd is 108.66 times as on 08-Jul-2026, a 203 premium to its peers’ median range of 35.92 times.
The P/B ratio of Astrazeneca Pharma India Ltd is 23.35 times as on 08-Jul-2026, a 366 premium to its peers’ median range of 5.01 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
185.90
|
28.19
|
|
2024
|
82.35
|
18.77
|
|
2023
|
81.76
|
13.85
|
|
2022
|
103.71
|
12.54
|
|
2021
|
80.66
|
16.55
|
What is the 52 Week High and Low of Astrazeneca Pharma India Ltd?
The 52-week high and low of Astrazeneca Pharma India Ltd are Rs 9,849.50 and Rs 7,551.50 as of 09-Jul-2026.
What is the market cap of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a market capitalisation of ₹ 20,375 Cr as on 08-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Astrazeneca Pharma India Ltd?
Before investing in Astrazeneca Pharma India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.